On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
BioBlast w/e 24 Nov 23
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P43, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion revealed in a corporate filing...